CE Geyer

492 total citations
23 papers, 262 citations indexed

About

CE Geyer is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, CE Geyer has authored 23 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 18 papers in Cancer Research and 16 papers in Oncology. Recurrent topics in CE Geyer's work include Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (16 papers) and Estrogen and related hormone effects (7 papers). CE Geyer is often cited by papers focused on Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (16 papers) and Estrogen and related hormone effects (7 papers). CE Geyer collaborates with scholars based in United States, Belgium and Switzerland. CE Geyer's co-authors include Norman Wolmark, EP Mamounas, SM Swain, Priya Rastogi, Soonmyung Paik, Louis Fehrenbacher, J. P. Costantino, JN Atkins, A. Robidoux and Adam Brufsky and has published in prestigious journals such as Cancer Research, Annals of Oncology and European Journal of Cancer.

In The Last Decade

CE Geyer

23 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
CE Geyer United States	9	217	148	74	71	54	23	262
SM Swain United States	9	237 1.1×	136 0.9×	109 1.5×	66 0.9×	36 0.7×	21	287
Clasina M. Venema Netherlands	9	133 0.6×	132 0.9×	165 2.2×	131 1.8×	70 1.3×	13	320
Jason Mouabbi United States	7	113 0.5×	100 0.7×	51 0.7×	64 0.9×	16 0.3×	41	205
Arielle J. Medford United States	8	139 0.6×	98 0.7×	38 0.5×	88 1.2×	17 0.3×	44	247
Marcelle Goldner Cesca Brazil	6	223 1.0×	99 0.7×	88 1.2×	76 1.1×	10 0.2×	18	272
Lillian M. Smyth United States	7	92 0.4×	62 0.4×	28 0.4×	46 0.6×	34 0.6×	24	166
Danai Fimereli Belgium	7	211 1.0×	140 0.9×	81 1.1×	67 0.9×	16 0.3×	10	294
Arisa Nishimukai Japan	8	142 0.7×	130 0.9×	103 1.4×	49 0.7×	18 0.3×	17	272
HJ Burstein United States	8	188 0.9×	84 0.6×	50 0.7×	61 0.9×	19 0.4×	25	223
Jorianne Boers Netherlands	10	155 0.7×	129 0.9×	131 1.8×	99 1.4×	46 0.9×	18	282

Countries citing papers authored by CE Geyer

Since Specialization

Citations

This map shows the geographic impact of CE Geyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by CE Geyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites CE Geyer more than expected).

Fields of papers citing papers by CE Geyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by CE Geyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by CE Geyer. The network helps show where CE Geyer may publish in the future.

Co-authorship network of co-authors of CE Geyer

This figure shows the co-authorship network connecting the top 25 collaborators of CE Geyer. A scholar is included among the top collaborators of CE Geyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with CE Geyer. CE Geyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tutt, Andrew, John J. Garber, R.D. Gelber, et al.. (2022). VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Annals of Oncology. 33(5). 566–568. 26 indexed citations

Untch, Michael, CE Geyer, Aleix Prat, et al.. (2021). Trastuzumab-Deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer (BC) after neoadjuvant therapy (NAT): a randomized, phase 3 trial (DESTINY-Breast05). Senologie - Zeitschrift für Mammadiagnostik und -therapie. 1 indexed citations

Loibl, Sibylle, Priya Rastogi, Sabine Seiler, et al.. (2020). 248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze). Annals of Oncology. 31. S339–S339. 2 indexed citations

Geyer, CE, Sibylle Loibl, Priya Rastogi, et al.. (2019). Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze. Cancer Research. 79(4_Supplement). OT3–5. 1 indexed citations

Láng, István, Eva Ciruelos, Meritxell Bellet, et al.. (2018). Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial. Cancer Research. 78(4_Supplement). GS4–3. 2 indexed citations

Pagani, Olivia, MM Regan, Marco Colleoni, et al.. (2018). Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. Cancer Research. 78(4_Supplement). GS4–2. 3 indexed citations

Fehrenbacher, L., CE Geyer, Priya Rastogi, et al.. (2018). Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Research. 78(4_Supplement). GS1–2. 40 indexed citations

Rastogi, Priya, CE Geyer, Louis Fehrenbacher, et al.. (2017). Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52. Cancer Research. 77(4_Supplement). S3–6. 29 indexed citations

Mamounas, EP, Hanna Bandos, BC Lembersky, et al.. (2017). Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. Cancer Research. 77(4_Supplement). S1–5. 37 indexed citations

10.

Gray, R, K. Pritchard, Kathy S. Albain, et al.. (2015). 5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. European Journal of Cancer. 51. S714–S714. 1 indexed citations

11.

Swain, SM, J. P. Costantino, Priya Rastogi, et al.. (2013). Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38. Cancer Research. 73(24_Supplement). PD2–1. 1 indexed citations

12.

Aebi, Stefan, Shari Gelber, István Láng, et al.. (2012). Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). Cancer Research. 72(24_Supplement). S3–2. 10 indexed citations

13.

Romond, Edward H., VJ Suman, CE Geyer, et al.. (2012). Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Cancer Research. 72(24_Supplement). S5–5. 33 indexed citations

14.

Láng, István, Michael Martin, EP Mamounas, et al.. (2012). Abstract P6-07-06: Patterns of locoregional failure in the CALOR (Chemotheraphy as Adjuvant for Locally Recurrent Breast Cancer) Trial. Cancer Research. 72(24_Supplement). P6–7. 1 indexed citations

15.

Lembersky, BC, Louis Fehrenbacher, CI Falkson, et al.. (2011). S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.. Cancer Research. 71(24_Supplement). S2–3. 14 indexed citations

16.

Bonneterre, Jacques, CE Geyer, Yasuaki Ito, et al.. (2011). S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.. Cancer Research. 71(24_Supplement). S5–7. 16 indexed citations

17.

Fehrenbacher, L., Priya Rastogi, CE Geyer, et al.. (2011). OT1-02-07: NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2−Low Invasive Breast Cancer.. Cancer Research. 71(24_Supplement). OT1–2. 3 indexed citations

18.

Swain, SM, Joon Jeong, CE Geyer, et al.. (2009). NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Cancer Research. 69(2_Supplement). 75–75. 21 indexed citations

19.

Ganz, PA, CE Geyer, J. P. Costantino, et al.. (2009). NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Cancer Research. 69(2_Supplement). 76–76. 3 indexed citations

20.

Geyer, CE, E. Mamounas, Lawrence Wickerham, et al.. (2007). P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33. The Breast. 16. S46–S46. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact